Chemomab Therapeutics Ltd
NASDAQ:CMMB
Chemomab Therapeutics Ltd
Research & Development
Chemomab Therapeutics Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chemomab Therapeutics Ltd
NASDAQ:CMMB
|
Research & Development
-$7.2m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Research & Development
-$12.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Research & Development
-$9.6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Research & Development
-$67.7m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Research & Development
-$5.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Research & Development
-₪10.7m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Chemomab Therapeutics Ltd
Glance View
Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
See Also
What is Chemomab Therapeutics Ltd's Research & Development?
Research & Development
-7.2m
USD
Based on the financial report for Sep 30, 2025, Chemomab Therapeutics Ltd's Research & Development amounts to -7.2m USD.
What is Chemomab Therapeutics Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-10%
Over the last year, the Research & Development growth was 40%. The average annual Research & Development growth rates for Chemomab Therapeutics Ltd have been 19% over the past three years , -10% over the past five years .
